June 2024, Vol 10, No. 6, Pages 697-835

This randomized clinical trial examines the efficacy of 1 or 2 immune checkpoint inhibitors combined with FOLFIRI in the treatment of advanced gastric/GEJ adenocarcinoma.

This cohort study examines the risk of a second primary breast cancer in women who were aged 40 years or younger when first diagnosed with breast cancer.

This report describes the development of an 18-gene urine panel for high-grade prostate cancer and validates its external performance relative to current guideline-endorsed biomarkers.

This nonrandomized controlled trial investigates the acute toxic effects of treatment with hypofractionated pelvic intensity-modulated radiotherapy and concurrent chemotherapy among women who experienced lymph node metastasis, parametrial invasion, or positive resection margins after radical hysterectomy for treatment of confirmed cervical cancer.

This systematic review and meta-analysis examines evidence regarding screening pathways incorporating magnetic resonance imaging with targeted biopsy and assess their diagnostic value compared with prostate-specific antigen–based screening with systematic biopsy strategies.

This nonrandomized clinical trial evaluates the efficacy and safety of a tailored approach with nivolumab plus ipilimumab as an immunotherapeutic boost in patients with metastatic urothelial carcinoma.

This cohort study examines the applicability of personalized colorectal cancer (CRC) screening with fecal-hemoglobin (f-Hb)-guided screening intervals to reduce the number of fecal immunological tests and colonoscopy, as well as determine if it demonstrates equivalent efficacy as universal biennial screening.

This cohort study examines the association of body composition with oncologic outcomes in patients receiving immunotherapy for advanced or metastatic non–small cell lung cancer.